• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

破解去分化脂肪肉瘤之谜:细胞外囊泡介导的MDM2是关键吗?

Cracking the riddle of dedifferentiated liposarcoma: is EV-MDM2 a key?

作者信息

Casadei Lucia, Pollock Raphael E

机构信息

The James Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio, USA.

Department of Surgery, Division of Surgical Oncology, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA.

出版信息

Oncoscience. 2020 Feb 1;7(1-2):10-13. doi: 10.18632/oncoscience.497. eCollection 2020 Jan.

DOI:10.18632/oncoscience.497
PMID:32258243
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7105156/
Abstract

Dedifferentiated liposarcoma (DDLPS) is molecularly characterized by wt p53 and MDM2 gene amplification causing MDM2 protein over-production, the key oncogenic process in DDLPS. Commonly located in fat-bearing retroperitoneal areas, almost 60% of DDLPS patients undergo multifocal recurrence, typically amenable to palliative treatment only, and occasionally develop distant metastasis. These factors lead to an abysmal 10% 10 year overall survival rate. Tumor cell-derived extracellular vesicles (EVs) can facilitate loco-regional malignancy dissemination by depositing molecular factors that participate in the development of pre-metastatic niches for tumor cell implantation and growth. High number of MDM2 DNA molecules was identified within EVs from DDLPS patient serum (ROC vs normal; 0.95) as well as from DDLPS cell lines. This MDM2 DNA could be transferred to preadipocytes (P-a), a major and ubiquitous cellular component of the DDLPS tumor microenvironment (TME), with subsequent P-a production of matrix metalloproteinase 2 (MMP2), a critical component in the metastatic cascade. From here the hypothesis that the DDLPS microenvironment (specifically P-a cells) may participate in DDLPS recurrence events. Since multifocal loco-regional DDLPS spreading is the main cause of the remarkably high lethality of this disease, a better understanding of the underlying oncogenic processes and their regulatory mechanisms is essential to improve the outcome of this devastating disease.

摘要

去分化脂肪肉瘤(DDLPS)的分子特征是野生型p53和MDM2基因扩增,导致MDM2蛋白过度产生,这是DDLPS中的关键致癌过程。DDLPS通常位于有脂肪的腹膜后区域,近60%的DDLPS患者会发生多灶性复发,通常仅适合姑息治疗,偶尔会发生远处转移。这些因素导致10年总生存率低至10%。肿瘤细胞衍生的细胞外囊泡(EVs)可通过沉积参与肿瘤细胞植入和生长的前转移微环境形成的分子因子,促进局部区域恶性肿瘤的扩散。在DDLPS患者血清的EVs(ROC与正常对照;0.95)以及DDLPS细胞系的EVs中均鉴定出大量MDM2 DNA分子。这种MDM2 DNA可转移至前脂肪细胞(P-a),P-a是DDLPS肿瘤微环境(TME)的主要且普遍存在的细胞成分,随后P-a会产生基质金属蛋白酶2(MMP2),这是转移级联反应中的关键成分。由此提出假说,即DDLPS微环境(特别是P-a细胞)可能参与DDLPS的复发事件。由于多灶性局部区域DDLPS扩散是该疾病高致死率的主要原因,更好地了解潜在的致癌过程及其调控机制对于改善这种毁灭性疾病的治疗结果至关重要。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/091a/7105156/2ab508d6cc26/oncoscience-07-010-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/091a/7105156/2ab508d6cc26/oncoscience-07-010-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/091a/7105156/2ab508d6cc26/oncoscience-07-010-g001.jpg

相似文献

1
Cracking the riddle of dedifferentiated liposarcoma: is EV-MDM2 a key?破解去分化脂肪肉瘤之谜:细胞外囊泡介导的MDM2是关键吗?
Oncoscience. 2020 Feb 1;7(1-2):10-13. doi: 10.18632/oncoscience.497. eCollection 2020 Jan.
2
Derived from Dedifferentiated Liposarcoma Extracellular Vesicles Induces MMP2 Production from Preadipocytes.源自去分化脂肪肉瘤细胞外囊泡诱导前脂肪细胞产生 MMP2。
Cancer Res. 2019 Oct 1;79(19):4911-4922. doi: 10.1158/0008-5472.CAN-19-0203. Epub 2019 Aug 6.
3
Degree of Amplification Affects Clinical Outcomes in Dedifferentiated Liposarcoma.扩增程度影响去分化脂肪肉瘤的临床结局。
Oncologist. 2019 Jul;24(7):989-996. doi: 10.1634/theoncologist.2019-0047. Epub 2019 Apr 24.
4
Extracellular vesicle cross-talk in the liposarcoma microenvironment.脂肪肉瘤微环境中的细胞外囊泡串扰。
Cancer Lett. 2020 Sep 1;487:27-33. doi: 10.1016/j.canlet.2020.04.026. Epub 2020 May 26.
5
Dedifferentiated liposarcoma and pleomorphic liposarcoma: a comparative study of cytomorphology and MDM2/CDK4 expression on fine-needle aspiration.去分化脂肪肉瘤和多形性脂肪肉瘤:细针抽吸细胞学形态学和 MDM2/CDK4 表达的比较研究。
Cancer Cytopathol. 2014 Feb;122(2):128-37. doi: 10.1002/cncy.21362. Epub 2013 Nov 12.
6
Brightline-1: phase II/III trial of the MDM2-p53 antagonist BI 907828 versus doxorubicin in patients with advanced DDLPS.BI 907828(MDM2-p53 拮抗剂)对比多柔比星治疗晚期去分化脂肪肉瘤的Ⅱ/Ⅲ期 Brightline-1 试验。
Future Oncol. 2023 Mar;19(9):621-629. doi: 10.2217/fon-2022-1291. Epub 2023 Mar 29.
7
Are peripheral purely undifferentiated pleomorphic sarcomas with MDM2 amplification dedifferentiated liposarcomas?外周部单纯未分化多形性肉瘤伴 MDM2 扩增是去分化脂肪肉瘤吗?
Am J Surg Pathol. 2014 Mar;38(3):293-304. doi: 10.1097/PAS.0000000000000131.
8
Correlation of histological grade of dedifferentiation with clinical outcome in 55 patients with dedifferentiated liposarcomas.55例去分化脂肪肉瘤患者去分化组织学分级与临床结局的相关性
Hum Pathol. 2017 Aug;66:86-92. doi: 10.1016/j.humpath.2017.02.015. Epub 2017 Mar 12.
9
MDM2-Dependent Rewiring of Metabolomic and Lipidomic Profiles in Dedifferentiated Liposarcoma Models.去分化脂肪肉瘤模型中依赖MDM2的代谢组学和脂质组学图谱重塑
Cancers (Basel). 2020 Aug 4;12(8):2157. doi: 10.3390/cancers12082157.
10
Anti-tumor activity of the MDM2-TP53 inhibitor BI-907828 in dedifferentiated liposarcoma patient-derived xenograft models harboring MDM2 amplification.MDM2-TP53抑制剂BI-907828在携带MDM2扩增的去分化脂肪肉瘤患者来源异种移植模型中的抗肿瘤活性。
Clin Transl Oncol. 2020 Apr;22(4):546-554. doi: 10.1007/s12094-019-02158-z. Epub 2019 Jun 14.

引用本文的文献

1
Comparison of three-dimensional cell culture techniques of dedifferentiated liposarcoma and their integration with future research.去分化脂肪肉瘤的三维细胞培养技术比较及其与未来研究的整合
Front Cell Dev Biol. 2024 Mar 4;12:1362696. doi: 10.3389/fcell.2024.1362696. eCollection 2024.
2
Cross-flow microfiltration for isolation, selective capture and release of liposarcoma extracellular vesicles.切向流微滤法用于分离、选择性捕获和释放脂肪肉瘤细胞外囊泡。
J Extracell Vesicles. 2021 Feb;10(4):e12062. doi: 10.1002/jev2.12062. Epub 2021 Feb 16.

本文引用的文献

1
Derived from Dedifferentiated Liposarcoma Extracellular Vesicles Induces MMP2 Production from Preadipocytes.源自去分化脂肪肉瘤细胞外囊泡诱导前脂肪细胞产生 MMP2。
Cancer Res. 2019 Oct 1;79(19):4911-4922. doi: 10.1158/0008-5472.CAN-19-0203. Epub 2019 Aug 6.
2
The Role of the Extracellular Matrix and Its Molecular and Cellular Regulators in Cancer Cell Plasticity.细胞外基质及其分子和细胞调节因子在癌细胞可塑性中的作用。
Front Oncol. 2018 Oct 9;8:431. doi: 10.3389/fonc.2018.00431. eCollection 2018.
3
Exosome-Derived miR-25-3p and miR-92a-3p Stimulate Liposarcoma Progression.
外泌体来源的miR-25-3p和miR-92a-3p促进脂肪肉瘤进展。
Cancer Res. 2017 Jul 15;77(14):3846-3856. doi: 10.1158/0008-5472.CAN-16-2984. Epub 2017 Jun 6.
4
Indication of Horizontal DNA Gene Transfer by Extracellular Vesicles.细胞外囊泡介导水平DNA基因转移的指征
PLoS One. 2016 Sep 29;11(9):e0163665. doi: 10.1371/journal.pone.0163665. eCollection 2016.
5
Adipose-Induced Retroperitoneal Soft Tissue Sarcoma Tumorigenesis: A Potential Crosstalk between Sarcoma and Fat Cells.脂肪诱导的腹膜后软组织肉瘤肿瘤发生:肉瘤与脂肪细胞之间的潜在相互作用。
Mol Cancer Res. 2016 Dec;14(12):1254-1265. doi: 10.1158/1541-7786.MCR-16-0131. Epub 2016 Sep 12.
6
Liposarcoma: molecular targets and therapeutic implications.脂肪肉瘤:分子靶点与治疗意义
Cell Mol Life Sci. 2016 Oct;73(19):3711-8. doi: 10.1007/s00018-016-2266-2. Epub 2016 May 12.
7
Exosomes released by chronic lymphocytic leukemia cells induce the transition of stromal cells into cancer-associated fibroblasts.慢性淋巴细胞白血病细胞释放的外泌体可诱导基质细胞转变为癌症相关成纤维细胞。
Blood. 2015 Aug 27;126(9):1106-17. doi: 10.1182/blood-2014-12-618025. Epub 2015 Jun 22.
8
Fluorescence In Situ Hybridization for MDM2 Amplification as a Routine Ancillary Diagnostic Tool for Suspected Well-Differentiated and Dedifferentiated Liposarcomas: Experience at a Tertiary Center.将MDM2基因扩增的荧光原位杂交作为疑似高分化和去分化脂肪肉瘤的常规辅助诊断工具:一家三级中心的经验
Sarcoma. 2015;2015:812089. doi: 10.1155/2015/812089. Epub 2015 Feb 25.
9
Extracellular vesicles derived from renal cancer stem cells induce a pro-tumorigenic phenotype in mesenchymal stromal cells.源自肾癌干细胞的细胞外囊泡在间充质基质细胞中诱导促肿瘤表型。
Oncotarget. 2015 Apr 10;6(10):7959-69. doi: 10.18632/oncotarget.3503.
10
Advances in the targeted therapy of liposarcoma.脂肪肉瘤靶向治疗的进展
Onco Targets Ther. 2015 Jan 5;8:125-36. doi: 10.2147/OTT.S72722. eCollection 2015.